RDNYSJATGQDZQN-DXBWTPJFSA-N

RDNYSJATGQDZQN-DXBWTPJFSA-N Suppliers list
Company Name: Tianjin Chempharmatech Co.,Ltd.  
Tel: 022-66211079 13212288319
Email: sales@chempharmatech.com
Company Name: Hygeia (Chengdu) pharmaceutical technique Co., Ltd  
Tel: 028-84502008 13568869383
Email: sales@hygeiapharm.com
Company Name: Shanghai Xingui Biotechnology Co., Ltd.  
Tel: 15121041756
Email: xingui2022@126.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Chengdu Zen Sunda Bio-pharmaceutical Technology Co., Ltd.  
Tel: 19981275275
Email: sales@zsdpharm.com
RDNYSJATGQDZQN-DXBWTPJFSA-N Basic information
Product Name:RDNYSJATGQDZQN-DXBWTPJFSA-N
Synonyms:RDNYSJATGQDZQN-DXBWTPJFSA-N;tert-butyl (S)-2-((1R,2R)-1-methoxy-3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 2-[(1R,2R)-1-methoxy-3-[[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]-2-methyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (2S)-; (S)-tert-butyl 2-((1R,2R)-1-methoxy-3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate;tert-Butyl (S)-2-((1R,2R)-1-methoxy-3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-methyl-3-ox;N-Boc-Dap-Phe-OMe;tert-butyl (S)-2-((1R,2R)-1-methoxy-3-(((R)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate;MMAF intermediate 1
CAS:161485-82-1
MF:C24H36N2O6
MW:448.55
EINECS:
Product Categories:
Mol File:161485-82-1.mol
RDNYSJATGQDZQN-DXBWTPJFSA-N Structure
RDNYSJATGQDZQN-DXBWTPJFSA-N Chemical Properties
Boiling point 582.891±45.00 °C(Press: 760.00 Torr)(predicted)
density 1.135±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
pka13.893±0.46(predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
RDNYSJATGQDZQN-DXBWTPJFSA-N Usage And Synthesis
UsesMMAF intermediate 1 is an intermediate in the synthesis of MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A[1].
References[1] Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70. [Content Brief] DOI:10.1158/1078-0432.CCR-10-0017
RDNYSJATGQDZQN-DXBWTPJFSA-N Preparation Products And Raw materials
Tag:RDNYSJATGQDZQN-DXBWTPJFSA-N(161485-82-1) Related Product Information
L-Phenylalanine, N-[(2R,3R)-3-methoxy-2-methyl-1-oxo-3-(2S)-2-pyrrolidinylpropyl]-, methyl ester, monohydrochloride (9CI) (S)-tert-butyl 2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate 1-Pyrrolidinecarboxylic acid, 2-[(1R,2S)-1-methoxy-3-[[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]-2-methyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (2S)- N-Boc-dolaproine-amide-Me-Phe 1-Pyrrolidinecarboxylic acid, 2-[(1R,2R)-3-[[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (2S)- (R,S,S,R,S)-Boc-Dap-NE